131030.KQ DHP Korea Co. Ltd
- Market cap
- KRW 101B
- P/E
- 7.4x
- P/B
- 0.56x
- ROE
- 7.1%
- Dividend yield
- -
- Fundamental score
- 2.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 131030.KQ undervalued?
Graham number131030.KQ trades 57.0% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DHP Korea Co. Ltd fundamental analysis
10 of 22 checks passedROE 0/2
Low return on equity (7.1%), below 10%.
ROA 1/1
Return on assets (6.5%) is above the industry median (3.4%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-3.1%) is not above the 5-year average (-6.2% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-3.1%) is below the industry median (6.6%).
Revenue Growth 2/2
Revenue grew 14.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
EBIT is 185.1x against interest expense, well covered.
PE vs Market 1/1
PE (7.4x) is below the market median (11.3x).
PE vs Industry 1/1
PE (7.4x) is below the industry median (19.4x).
PBV 1/1
Price to book (0.6x) is below the industry median (0.8x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 4.2, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
DHP Korea Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DHP Korea Co. Ltd
OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was fo…
Full company profileDHP Korea Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DHP Korea Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 44.7B | 49.8B | 49.6B | 60.4B | 60.8B | 57.3B | 58.7B | 72.4B | 81.9B | 87.2B | 95.7B |
| Gross Profit | 25.1B | 27.7B | 27.1B | 36.9B | 38.3B | 32.5B | 31.7B | 41.4B | 44.7B | 48.2B | 56.0B |
| Operating Income | 11.4B | 12.6B | 10.7B | 15.2B | 15.5B | 10.5B | 5.26B | 8.19B | 8.59B | 8.88B | 10.4B |
| EBITDA | - | - | - | - | - | - | 10.4B | 17.3B | 16.2B | 15.8B | 20.1B |
| Net Income | 11.5B | 12.9B | 10.0B | 14.6B | 14.4B | 9.89B | 5.01B | 10.8B | 10.3B | 11.4B | 12.8B |
| EPS | 704 | 789 | 613 | 894 | 898 | 617 | 330 | 705 | 674 | 654 | 739 |
| Balance Sheet | |||||||||||
| Total Assets | 83.8B | 94.6B | 104B | 119B | 130B | 140B | 136B | 149B | 167B | 191B | 198B |
| Total Liabilities | 8.59B | 8.02B | 9.00B | 11.2B | 11.0B | 13.0B | 11.8B | 15.0B | 22.8B | 26.1B | 17.7B |
| Shareholders' Equity | 75.3B | 86.6B | 94.9B | 108B | 119B | 127B | 124B | 134B | 144B | 165B | 180B |
| Cash & Short-term Investments | 43.0B | 54.4B | 59.2B | 69.2B | 77.4B | 69.6B | 61.6B | 57.8B | 51.4B | 20.7B | 7.02B |
| Total Debt | - | - | - | 72.9M | 352M | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 12.0B | 18.3B | 15.0B | 16.8B | 17.4B | 7.07B | 2.05B | 12.4B | 8.90B | 16.2B | 18.1B |
| Capital Expenditure | 1.65B | 1.16B | 689M | 3.80B | 5.84B | 10.6B | 6.00B | 3.33B | 25.7B | 45.0B | 41.6B |
| Free Cash Flow | - | - | - | - | 11.6B | -3.56B | -3.96B | 9.11B | -16.8B | -28.8B | -23.4B |
| Ratios | |||||||||||
| ROE | 15.3% | 14.9% | 10.5% | 13.5% | 12.1% | 7.8% | 4.0% | 8.0% | 7.2% | 6.9% | 7.1% |
| ROA | 13.7% | 13.6% | 9.6% | 12.3% | 11.1% | 7.1% | 3.7% | 7.2% | 6.2% | 5.9% | 6.5% |
| Net Profit Margin | 25.7% | 25.9% | 20.2% | 24.1% | 23.7% | 17.3% | 8.5% | 14.9% | 12.6% | 13.0% | 13.4% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DHP Korea Co. Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 27, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | KRW 1.53B | 100 | 14.8% |
| 2023 | KRW 1.52B | 99 | 14.1% |
| 2022 | KRW 1.60B | 106 | 32.0% |
| 2021 | KRW 1.60B | 100 | 16.2% |
| 2020 | KRW 1.63B | 102 | 11.3% |
| 2019 | KRW 1.63B | 100 | 11.2% |
| 2018 | KRW 1.63B | 100 | 16.3% |
| 2017 | KRW 1.63B | 100 | 12.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns DHP Korea Co. Ltd
- Insiders 46.38%
- Institutions 0.21%
- Public & others 53.41%
- Shares outstanding 17.4M
- Free float 9.31M
DHP Korea Co. Ltd company profile
- Company name
- DHP Korea Co. Ltd
- Ticker
- 131030.KQ
- ISIN
- KR7131030009
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 50 Osongsaengmyeong 6-ro, Cheongju, South Korea
- Phone
- 82 2 2118 0030
- Website
- optuspharm.com
About DHP Korea Co. Ltd
OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea.
DHP Korea Co. Ltd management
1- Mr. Dong-Hwa HanChief Executive Officer and President